Protein kinase C-theta inhibitors: A novel therapy for inflammatory disorders

Current Pharmaceutical Design

Volumn 18, Issue 30, 2012, Pages 4725-4746

  Chand, Sukhvir ^a   Mehta, Nisha ^a   Bahia, Malkeet Singh ^a   Dixit, Anshuman ^b   Silakari, Om ^a  

^a PUNJABI UNIVERSITY   (India)

^b INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Autoimmune diseases; Diacylglycerol (DAG); NF kB; Protein kinase C theta (PKC ); Rheumatoid arthritis (RA)

Indexed keywords

BENZENE DERIVATIVE; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; DIETHYLAMINE; INDOLE DERIVATIVE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MORPHOLINE DERIVATIVE; PHOSPHOLIPASE C; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C IOTA; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C MU; PROTEIN KINASE C THETA; PROTEIN KINASE C THETA INHIBITOR; PROTEIN KINASE C ZETA; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; STAUROSPORINE; THIENO[2,3 B]PYRIDINE DERIVATIVE; THIOMORPHOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; AMINO ACID SUBSTITUTION; ASTHMA; AUTOIMMUNE DISEASE; AUTOPHOSPHORYLATION; CALCIUM BINDING; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENDOPLASMIC RETICULUM; ENTERITIS; ENZYME INHIBITION; ENZYME STABILITY; MOLECULAR DOCKING; MULTIPLE SCLEROSIS; NONHUMAN; ORGAN TRANSPLANTATION; PHARMACOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEREOISOMERISM;

AMINO ACID SEQUENCE; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CATALYTIC DOMAIN; DRUG DESIGN; HUMANS; INTERLEUKIN-2; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 84866354416     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802651625     Document Type: Review

References (90)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
2. Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell 2010; 140: 771-776.
3. Libby P. Inflammatory mechanisms: The molecular basis of inflammation and disease. Nutr Rev 2007; 65: 140-146.
4. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: State of the art, definitions and terms. FASEB J 2007; 21: 325-332.
5. Barton GM. A calculated response: Control of inflammation by the innate immune system. J Clin Invest 2008; 118: 413-420.
6. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852.
7. Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nature Immunol 2005; 6: 1191-1197.
8. Serhan CN. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137.
9. Rock KL, Kono H. The inflammatory response to cell death. Annu Rev Pathol 2008; 3: 99-126.
10. Assari T. Chronic granulomatous disease: Fundamental stages in our understanding of CGD. Med Immunol 2006; 5: 1-8.
11. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: Importance of NOD2 and NALP3 in interleukin-1θ generation. Clin Exp Immunol 2007; 147: 227-235.
12. Gorman C, Park A. Inflammation is a secret killer: A surprising link between inflammation and asthma, heart attacks, cancer, Alzheimer's and other diseases. Time Magazine Feb 23, 2004.
13. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatr 2003; 74: 1200-1205.
14. McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer's disease. Can J Neurol Sci 1989; 16: 516-527.
15. Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol 2007; 184: 69-91.
16. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007; 42: 3-27.
17. Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 2001; 44: 437-450.
18. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: Critical remarks. Curr Med Chem 2002; 10: 1033-1043.
19. Available from: http://www.vioxxnews.com/ [accessed on Nov 29,2011].
20. Celotti F, Laufer S. Anti-inflammatory drugs: New multi-targetcompounds to face an old problem: The dual inhibition concept. Pharmacol Res 2001; 43: 429-436.
21. Hayashi K, Altman A. Protein Kinase C Theta (PKC-θ): A key player in T cell life and death. Pharmacol Res 2007; 55: 537-544.
22. Baier G, Telford D, Giampa L, et al. Molecular cloning and characterization of PKC θ: A human novel member of the protein kinase C (PKC) gene family expressed predominantly in hematopoietic cells. J Biol Chem 1993; 268: 4997-5004.
23. Anderson K, Fitzgerald M, Dupont M, et al. Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell mediated inflammatory diseases. Autoimmunity 2006; 39: 469-478.
24. DeClercq C, Demers D, Bree A, et al. Specific blockade of protein kinase C (PKC)-theta with a small molecule antagonist attenuates lung inflammation in a mouse model of established allergic airway disease. J Immunol 2009; 182: 140.21.
25. Nagahama K, Ogawa A, Shirane K, Shimomura Y, Sugimoto K, Mizoguchi A. Protein kinase C theta plays a fundamental role in different types of chronic colitis. Gastroenterology 2008; 134: 459-469.
26. Garaude J, Kaminski S, Charni S, et al. Impaired anti-leukemic immune response in PKC-θ deficient mice. Mol Immunol 2008; 45: 3463-3469.
27. Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 2000; 279: L429-L438.
28. Sabri A, Steinberg SF. Protein kinase C isoform selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 2003; 251: 97-101.
29. Steinberg SF. Structural basis of protein kinase C isoform function. Physiol Rev 2008; 88: 1341-1378.
30. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
31. Ali AS, Ali S, El-Rayes BF, Philip PA, Sarkar FH. Exploitation of protein kinase C: A useful target for cancer therapy. Cancer Treat Rev 2009; 35: 1-8.
32. Palaniyandi SS, Sun L, Ferreira JC, Mochly-Rosen D. Protein kinase C in heart failure: A therapeutic target. Cardiovasc Res 2009; 82: 229-239.
33. Gonelli A, Mischiati C, Guerrini R, Voltan R, Salvadori S, Zauli G. Perspectives of protein kinase C (PKC) inhibitors as anti-cancer agents. Mini Rev Med Chem 2009; 9: 498-509.
34. Bynagari-Settipalli YS, Chari R, Kilpatrick L, Kunapuli SP. Protein kinase C-possible therapeutic target to treat cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 2010; 10: 292-308.
35. Churchill E, Budas G, Vallentin A, Koyanagi T, Mochly-Rosen D. PKC isozymes in chronic cardiac disease: Possible therapeutic targets. Annu Rev Pharmacol Toxicol 2008; 48: 569-599.
36. Newton AC. Protein kinase C: structure, function and regulation. J Biol Chem 1995; 270: 28495-28498.
37. Mellor H, Parker J. The extended protein kinase C superfamily. Biochem J 1998; 332: 281-292.
38. Selbie LA, Schmitz-Peiffer C, Sheng Y, Biden TJ. Molecular cloning and characterization of PKC iota, an atypical isoform of protein kinase C derived from insulin secreting cells. J Biol Chem 1993; 268: 24296-24302.
39. Crabos M, Imber R, Woodtli T, Fabbro D, Erne P. Different translocation of three distinct PKC isoforms with tumor promoting phorbol ester in human platelets. Biochem Biophys Res Commun 1991; 178: 878-883.
40. Pelech SL, Samiei M, Charest DL, Howard SL, Salari H. Characterization of calcium independent forms of protein kinase C-beta in phorbol ester treated rabbit platelets. J Biol Chem 1991; 266: 8696-8705.
41. Wang F, Naik UP, Ehrlich YH, et al. A new protein kinase C, nPKC eta and nPKC theta are expressed in human platelets: Involvement of nPKC eta and nPKC theta in signal transduction stimulated by PAF. Biochem Biophys Res Commun 1993; 191: 240-246.
42. Osada S, Mizuno K, Saido TC, et al. A phorbol ester receptor/ protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin. J Biol Chem 1990; 265: 22434-440.
43. Osada S, Mizuno K, Saido TC, Suzuki K, Kuroki T, Ohno S. A new member of the protein kinase C family, nPKC theta, predominantly expressed in skeletal muscle. Mol Cell Biol 1992; 12: 3930-3938.
44. Ono Y, Fujii T, Ogita K, Kikkawa U, Igarashi K, Nishizuka Y. The structure, expression, and properties of additional members of the protein kinase C family. J Biol Chem 1988; 263: 6927-6932.
45. Mannicasammy S, Gupta S, Sun Z. Selective function of PKC- θ in T-cells. Cell Mol Immunol 2006; 3: 263-270.
46. Arendt CW, Albrecht B, Soos TJ, Littman DR. Protein kinase Ctheta: Signaling from the center of the T-cell synapse. Curr Opin Immunol 2002; 14: 323-330.
47. Nakamura S, Yamamura H. Yasutominishizuka: Father of protein kinase C. Biochem J 2010; 148: 125-130.
48. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol 1997; 9: 161-167.
49. Yamasaki T, Takahashi A, Pan J, Yamaguchi N, Yokoyama KK. Phosphorylation of activation transcription factor-2 at serine 121 by protein kinase C controls c-Jun mediated activation of transcription. J Biol Chem 2009; 284: 8567-8581.
50. Thuille N, Heit I, Fresser F, et al. Critical role of novel Thr-219 autophosphorylation for the cellular function of PKC θ in T lymphocytes. EMBO J 2005; 24: 3869-3880.
51. Czerwinski R, Aulabaugh A, Greco RM, et al. Characterization of protein kinase C-θ activation loop auto-phosphorylation and the kinase domain catalytic mechanism. Biochemistry 2005; 44: 9563-9573.
52. Xu ZB, Chaudhary D, Olland S, et al. Catalytic domain crystal structure of protein kinase C-θ (PKC-θ). J Biol Chem 2004; 279: 50401-50409.
53. Liu Y, Witte S, Liu YC, Doyle M, Elly C, Altman A. Regulation of protein kinase C-θ function during T cell activation by Lck mediated tyrosine phosphorylation. J Biol Chem 2000; 275: 3603-3609.
54. Liu Y, Graham C, Li A, Fisher R J, Shaw S. Phosphorylation of the protein kinase C-theta activation loop and hydrophobic motif regulates its kinase activity, but only activation loop phosphorylation is critical to in vivo nuclear factor-kappaB induction. Biochem J 2002; 361: 255-265.
55. Altman A, Villalba M. Protein kinase C-theta (PKCtheta): It's all about location, location, location. Immunol Rev 2003; 192: 53-63.
56. Isakov N, Altman A. Protein kinase C-θ in T-cell activation. Ann Rev Immunol 2002; 20: 761-794
57. Sun Z, Arendt CW, Ellmeier W, et al. PKC-θ is required for TCR induced NF-θB activation in mature but not immature T lymphocytes. Nature 2000; 404: 402-407.
58. Pfeifhofer C, Kofler K, Gruber T, et al. PKC-θaffects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med 2003; 197: 1525-1535.
59. Altman A, Kaminski S, Busuttil V, et al. Positive feedback regulation of PLCgamma1/Ca2+ signaling by PKCtheta in restimulated T cells via a Tec kinase dependent pathway. Eur J Immunol 2004; 34: 2001-2011.
60. Manicassamy S, Gupta S, Sun Z. Selective function of PKC-theta in T cells. Cell Mol Immunol 2006; 3: 263-270.
61. Healy AM, Izmailova E, Fitzgerald M, et al. PKC-theta deficient mice are protected from Th1-dependent antigen induced arthritis. J Immunol 2006; 177: 1886-1893.
62. Available from http://www.rigel.com/rigel/PKC [Accessed on 11 July 2011].
63. Boschelli DH. Small molecule inhibitors of PKC-theta as potential anti-inflammatory therapeutics. Curr Top Med Chem 2009; 9: 640-654.
64. Pratt JC, Igras VE, Maeda H, et al. Cutting edge: Gab2 mediates an inhibitory phosphatidylinositol 3'-kinase pathway in T cell antigen receptor signaling. J Immunol 2000; 165: 4158-4163.
65. Lin J, Weiss A. T cell receptor signaling. J Cell Sci 2001; 114: 243-244.
66. Okkenhaug K, Bilancio A, Emery JL, Vanhaesebroeck B. Phosphoinositide 3-kinase in T cell activation and survival. Biochem Soc Trans 2004; 32: 332-35.
67. Available from: http://www.sabiosciences.com/pathway.php?sn=TCRSignaling
68. Perez-Villar JJ, Whitney GS, Sitnick MT, et al. Phosphorylation of the linker for activation of T-cells by ITK promotes recruitment of Vav. Biochemistry 2002; 41: 10732-10740.
69. Coll T, Eyre E, Rodríguez-Calvo R, et al. Oleate reverses palmitate induced insulin resistance and inflammation in skeletal muscle cells. J Biol Chem 2008; 283: 11107-11116.
70. Tak PP, Firestein GS. NF-θB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
71. McAllister-Lucas LM, Inohara N, Lucas PC, et al. BIMP1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-θB induction. J Biol Chem 2001; 276: 30589-30597.
72. Langell FD, Jain NA, Rossman JS, Kingeter LM, Kashyap AK, Schaefer BC. Multiple protein domains mediate interaction between Bcl10and MALT1. J Biol Chem 2008; 283: 32419-324131.
73. Cywin CL, Dahmann G, Prokopowicz AS, et al. Discovery of potent and selective PKC-θ inhibitors. Bioorg Med Chem Lett 2007; 17: 225-230.
74. Cole DC, Asselin M, Brennan A, et al. Identification, characterizationand initial hit-to-lead optimization of a series of 4-arylamino- 3-pyridinecarbonitrile as protein kinase c theta (PKC-θ) inhibitors. J Med Chem 2008; 51: 5958-5963.
75. Dushin RG, Nittoli T, Ingalls C, et al. Synthesis and PKC-θ inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles. Bioorg Med Chem Lett 2009; 19: 2461-2463.
76. Boschelli DH, Wang D, Prashad AS, et al. Optimization of 5- phenyl-3-pyridinecarbonitriles as PKC-θ inhibitors. Bioorg Med Chem Lett 2009; 19: 3623-3626.
77. Shim J, Eid C, Lee J, Liu E, Chaudhary D, Boschelli DH. Synthesis and PKC-θ inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles. Bioorg Med Chem Lett 2009; 19: 6575-6577.
78. Niu C, Boschelli DH, Tumey LN, et al. First generation 5-vinyl-3-pyridinecarbonitrile PKC-θ inhibitors. Bioorg Med Chem Lett 2009; 19: 5829,32.
79. Prashad AS, Wang D, Subrath J, et al. C-5 substituted heteroaryl-3- pyridinecarbonitriles as PKC-θ inhibitors: part II. Bioorg Med Chem Lett 2009; 19: 5799-5802.
80. Tumey LN, Bhagirath N, Brennan A, Brooijmans N, Lee J, Yang X, Boschelli DH. 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKC- θ: optimization of enzymatic and functional activity. Bioorg Med Chem Lett 2009; 17: 7933-7948.
81. Boschelli DH, Subrath J, Niu C, et al. Optimization of 5-vinylaryl- 3-pyridinecarbonitriles as PKC-θ inhibitors. Bioorg Med Chem Lett 2010; 20: 1965-1968.
82. Wu B, Boschelli DH, Lee J, Yang X, Chaudhary D. Second generation4-(4-methyl-1H-indol-5-ylamino)- 2-phenylthieno[2,3- b]pyridine-5-carbonitrile PKC-θ inhibitors. Bioorg Med Chem Lett 2009; 19: 766-769.
83. Boschelli DH, Wu B, Barrios-Sosa AC, et al. Synthesis and PKC-θ inhibitory activity of a series of 4-(indol-5-ylamino) thieno[2,3- b]pyridine-5-carbonitriles. Bioorg Med Chem Lett 2008; 18: 2850-2853.
84. Nathan TL, Boschelli DH, Lee J, Chaudhary D. 2-Alkenylthieno [2,3-b]pyridine-5-carbonitriles: Potent and selective inhibitors of PKC-θ. Bioorg Med Chem Lett 2008; 18: 4420-4423.
85. Wagner J, Von-Matt P, Sedrani R, et al. Discovery of 3-(1H-Indol- 3-yl)-4- [2-(4-methylpiperazin-1-yl)quinazolin-4-yl]- pyrrole-2,5- dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes. J Med Chem 2009; 52: 6193-6196.
86. Mecklenbraeuker I, Saijo K, Zheng NY, Leitges M, Tarakhovsky A. Protein kinase C-θ controls self antigen induced B-cell tolerance. Nature 2002; 416: 860-865.
87. Fabbro D, Ruetz S, Bodis S, et al. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des 2000; 15: 17-28.
88. Sorbera LA, Serradell N, Bolos J, Rosa E. Enzastaurin hydrochloride. Protein kinase C-θ inhibitor, Antiangiogenic agent. Drugs Fut 2007; 32: 297.
89. Taulien CA, Joy SV. Ruboxistaurin. Drugs Today 2006; 42: 577-585.
90. Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008; 118: 3151-3159.